Oncology - Breast cancer, Oncology - Ovarian cancer
Conditions
Brief summary
PFS of patients with relapsed ovarian cancer treated according to zAvatar-test-based therapeutic decision and those treated according to clinical-choice (standard of care)., PFS of metastatic breast cancer patients treated according to zAvatar-test-based therapeutic decision and those treated according to clinical-choice (standard of care).
Detailed description
Response rate (RR) and overall survival (OS) of relapsed ovarian cancer patients treated according to zAvatar-based therapeutic decision and those treated according to clinical-choice (standard of care)., RR and OS of metastatic breast cancer patients treated according to zAvatar-based therapeutic decision and those treated according to clinical-choice (standard of care)., Describe HCS utilization between both treatment arms for both disease – relapsed ovarian cancer and metastatic breast cancer., Sequence selected multi-resistant/multi-sensitive responders/non-responders tumors, at the transcriptomic (single-cell) level (scRNAseq)
Interventions
DRUGGEMCITABINE HYDROCHLORIDE
DRUGEVEROLIMUS
DRUGEPIRUBICIN HYDROCHLORIDE
DRUGPACLITAXEL
DRUGDOXORUBICIN HYDROCHLORIDE
DRUGLIPOSOMAL
DRUGOLAPARIB
DRUGPALBOCICLIB
DRUGMIRVETUXIMAB SORAVTANSINE
DRUGTOPOTECAN
DRUGBEVACIZUMAB
DRUGDOCETAXEL
DRUGCYCLOPHOSPHAMIDE
DRUGERIBULIN MESYLATE
DRUGRIBOCICLIB
DRUGCARBOPLATIN
DRUGTRASTUZUMAB DERUXTECAN
DRUGALPELISIB
DRUGABEMACICLIB
DRUGFULVESTRANT
DRUGPEMBROLIZUMAB
DRUGVINORELBINE
DRUGATEZOLIZUMAB
DRUGTALAZOPARIB
DRUGEXEMESTANE
DRUGSACITUZUMAB GOVITECAN
DRUGCAPECITABINE
DRUGETOPOSIDE
Sponsors
Rita Fior, Champalimaud Clinical Centre, Rita Fior
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS of patients with relapsed ovarian cancer treated according to zAvatar-test-based therapeutic decision and those treated according to clinical-choice (standard of care)., PFS of metastatic breast cancer patients treated according to zAvatar-test-based therapeutic decision and those treated according to clinical-choice (standard of care). | — |
Secondary
| Measure | Time frame |
|---|---|
| Response rate (RR) and overall survival (OS) of relapsed ovarian cancer patients treated according to zAvatar-based therapeutic decision and those treated according to clinical-choice (standard of care)., RR and OS of metastatic breast cancer patients treated according to zAvatar-based therapeutic decision and those treated according to clinical-choice (standard of care)., Describe HCS utilization between both treatment arms for both disease – relapsed ovarian cancer and metastatic breast cancer., Sequence selected multi-resistant/multi-sensitive responders/non-responders tumors, at the transcriptomic (single-cell) level (scRNAseq) | — |
Countries
Portugal
Outcome results
None listed